Skip to main content
News & Press Releases

Imagin Engages Kilmer Lucas for Cross-border Investor Relations

By 21 June 2018August 11th, 2022No Comments

Vancouver, BC and Boston, MA, June 20, 2018 – Imagin Medical (CSE: IME) (OTCPINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that it has engaged Kilmer Lucas Inc. (“Kilmer Lucas”) to provide the Company with select U.S. and Canadian investor relations (“IR”) and strategic advisory services.

Employing an ‘outsourced in-house’ partnership model, Kilmer Lucas designs and executes customized IR programs for medical device, drug development, cell therapy, diagnostics and healthcare services companies.

“As we continue to gain momentum, our product development activities escalate, and we begin to execute other key facets of our growth strategy, we are confident that Kilmer Lucas is the right partner to help us communicate our progress to a broader investor audience in both the U.S. and Canada,” said Jim Hutchens, Imagin’s President and CEO.

“Imagin’s senior management team has a strong track record of accomplishment in the global medical device industry,” commented Kilmer Lucas’ founder and President, Stephen Kilmer. “That, combined with the Company’s positioning at the forefront of the next wave in medical imaging technology, provides the foundation for a great investment story, and we are excited that Imagin has chosen us to help tell it. Through the provision of a full range of IR and strategic advisory services, our primary goals will be to assist Imagin in achieving a fair and sustainable market valuation and to enhance the reputation that it carries in the minds of its various stakeholders, including investors, analysts and members of the media.”

About Kilmer Lucas

Kilmer Lucas is the first and only cross-border, healthcare-focused investor relations and capital markets advisory firm. It takes a holistic approach to building a customized IR strategy, that begins with a deep understanding of a company’s corporate and financial goals. Kilmer Lucas seeks to leverage its longstanding relationships and strong track record to positively influence investor perceptions, maximize stock valuations and lower the cost of capital needed to fund its clients’ growth. Since 2009, the firm has also published the popular healthcare investor news blog and e-letter, BioTuesdays. Todate, BioTuesdays has profiled more than 350 healthcare companies, providing invaluable exposure for innovative technologies and compelling investment stories that may have otherwise gone unnoticed. More information about the firm can be found at

About Imagin Medical

Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The Company believes its technology will radically improve physicians’ ability to detect cancer with minimally invasive endoscopes and reduce recurrence by dramatically improving their ability to visualize, identify and remove cancerous cells. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S., and the costliest cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin’s advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.


Jim Hutchens, President & CEO
Telephone: 833-246-2446
Email: [email protected]

Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: [email protected]